Profile

Business Description

Sangamo Therapeutics is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences.

Company Info

Address:
Point Richmond Tech Center II
501 Canal Blvd
Richmond, CA 94804

Telephone:
(510) 970-6000

Fax:
(510) 236-8951

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Biological Product (Except Diagnostic) Manufacturing (325414)

SIC:
Biological Products, Except Diagnostic Substances (2836)

Sign Up For E-Mail Alerts

Sign Up